CELG
Subscriber Request Series: Celgene Corp (NAS:CELG) and Bristol Myers (NYS:BMY)
2019-07-11
FAST Graphs Analyze Out Loud Celgene Corp $CELG: Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include REVLIMID, POMALYST, IMNOVID, OTEZLA, ABRAXANE, and VIDAZA. The company was founded by David Stirling and […]
When is the PEG Ratio Superior to the P/E Ratio? Part 2
2016-11-03
Introduction Financial metrics such as P/E ratios, price to cash flow ratios, PEG ratios, price to sales ratios, price to book value, and many others, should be thought of as tools in the investor’s toolbox. They can all be useful when appropriately utilized towards putting together a successful stock portfolio. However, just as you wouldn’t […]
5 Attractive Biotechnology Stocks for Healthy Long-term Returns
2016-06-10
Introduction I am a fervent believer that investors are best served by investing towards a specific investment objective that suits their own unique goals, objectives and risk tolerance. In other words, investing is not always trying to get the highest possible total returns. If that were true, no one would have ever invested in bonds, […]
Celgene: A Primer on Growth Stock Value Investing (GARP): Part 2
2015-11-13
Introduction This article is the second in a two-part series on applying the principles of value investing. In part 1 found here my primary focus was on the benefits of investing in fundamentally strong dividend growth stocks when they are out of favor, and therefore, undervalued as a result. In this part 2, I will […]
Choosing Common Stocks That Make Sense for Your Retirement Portfolio: Part 2
2015-09-17
Introduction Choosing the most appropriate stocks for the common stock portion of your retirement portfolio is vitally important. In part 1 of this series found here I presented the 6 broad categories of stocks (businesses) that renowned mutual fund manager Peter Lynch presented in his best-selling book “One Up On Wall Street.” I contend that […]
Trying To Beat The Market Is A Fool’s Errand
2013-10-17
Introduction Proponents of indexing as the best investment strategy seemed to take great delight in reporting how the vast majority of professionally managed portfolios (mutual funds, separately managed accounts, hedge funds, ETFs, etc.) fail to outperform the S&P 500. Therefore, they argue, it is best not to even try. Investors should simply invest in index […]